bims-mibica Biomed News
on Mitochondrial bioenergetics in cancer
Issue of 2026–11–15
nine papers selected by
Kelsey Fisher-Wellman, Wake Forest University



  1. Cells. 2026 Oct 27. pii: 1955. [Epub ahead of print]15(21):
      Metabolic reprogramming is increasingly recognized as a fundamental component of acute myeloid leukemia (AML) biology, but AML cannot be defined by a single metabolic phenotype. Leukemic cells occupy dynamic metabolic states shaped by differentiation, genetic background, the bone marrow microenvironment, and therapeutic pressure. In this Review, we propose that metabolic biomarkers should capture functional dependencies and metabolic plasticity rather than static metabolic states, with functional dependencies defined as the reliance of AML cells on a specific metabolic pathway or process for their survival, proliferation or maintenance, rather than a simple glycolytic-versus-oxidative dichotomy. Normal hematopoietic stem cells (HSCs), leukemic stem cells (LSCs), and bulk AML blasts display distinct metabolic programs. Quiescent HSCs maintain a low-energy state, whereas LSCs rely strongly on mitochondrial oxidative phosphorylation (OXPHOS), amino acid metabolism, mitochondrial quality control, and antioxidant defenses. AML blasts exhibit greater metabolic heterogeneity and can switch between glycolytic and oxidative pathways. Importantly, increased mitochondrial activity does not necessarily indicate an LSC phenotype, as therapy-resistant AML cells may acquire enhanced OXPHOS, fatty acid oxidation (FAO), and mitochondrial fitness as adaptive states. Acute promyelocytic leukemia (APL) provides a model of lineage-specific metabolic rewiring, with PML::RARA suppressing glycolysis while promoting FAO, TCA cycle activity, OXPHOS, and arginine-associated anaplerosis. We propose that metabolic biomarkers should identify functional dependencies and escape routes. Integrating metabolic profiling with multi-omics approaches may enable identification of AML subgroups with distinct vulnerabilities and guide rational combination therapies.
    Keywords:  acute myeloid leukemia; acute promyelocytic leukemia; fatty acid oxidation; glycolysis; leukemic stem cells; metabolic dependencies; metabolic heterogeneity; oxidative phosphorylation; redox; therapeutic resistance
    DOI:  https://doi.org/10.3390/cells15211955
  2. bioRxiv. 2026 Oct 20. pii: 2026.10.18.759986. [Epub ahead of print]
      Metabolic state is tightly linked to cell fate, and expression of the mitochondrial pyruvate carrier (MPC), which imports pyruvate into mitochondria, is a robust marker of it. The transcriptional regulators that set metabolic state, however, remain poorly defined. In the liver, β-catenin is one of the determinants of metabolic zonation, and activating CTNNB1 mutations are frequent in hepatocellular carcinoma. Here we show that β-catenin regulates metabolic state in liver cancer cells. An unbiased CRISPR screen that uses endogenous MPC1 transcript abundance as the marker identifies CTNNB1 . Activating β-catenin pharmacologically or genetically reduces MPC1 and MPC2 transcript and protein levels, and MPC expression is also low in β-catenin-driven liver tumors in vivo. Beyond the MPC, β-catenin activation impairs assembly of respiratory Complexes III and IV, reduces mitochondrial DNA content and respiratory capacity, elongates mitochondrial networks and remodels the lipidome. Stable isotope tracing shows reduced entry of glucose- and lactate-derived carbon into the TCA cycle alongside increased oxidation of palmitate and oleate. These findings identify β-catenin as a regulator of metabolic state that drives a fuel switch from carbohydrate to fatty acid oxidation in liver cancer cells.
    DOI:  https://doi.org/10.64898/2026.10.18.759986
  3. bioRxiv. 2026 Oct 20. pii: 2026.10.18.759957. [Epub ahead of print]
      Mutations in isocitrate dehydrogenase 1 or 2 (mIDH) generate the oncometabolite D-2-hydroxyglutarate that drives tumorigenesis in a distinct molecular class of gliomas. The mIDH inhibitor vorasidenib slows tumor growth, but disease progression remains a challenge, identifying a need for strategies that deepen and prolong therapeutic response. Here, we show that glucagon-like peptide-1R (GLP1R) agonists synergize with vorasidenib in patient-derived and murine models of mIDH glioma. Mechanistically, GLP1R agonists activate cAMP-protein kinase A signaling and induce nitric oxide synthase 1-dependent nitric oxide production in mIDH glioma cells. Nitric oxide inhibits aconitase and ribonucleotide reductase via S-nitrosylation, thereby disrupting the tricarboxylic acid cycle, depleting deoxyribonucleotides, blocking DNA synthesis, and exerting a cytostatic inhibition of tumor cell proliferation. Concomitantly, vorasidenib relieves D-2HG-driven suppression of pyruvate dehydrogenase, thereby increasing mitochondrial superoxide production and suppressing proliferation without cytotoxicity. When combined, GLP1R agonist-induced nitric oxide and vorasidenib-induced superoxide converge to generate peroxynitrite, which damages lipids and DNA, and triggers apoptosis in mIDH glioma cells. Combining a GLP1R agonist with vorasidenib recapitulates these metabolic and pharmacodynamic effects in mice bearing intracranial mIDH tumors, induces tumor regression, and significantly prolongs survival relative to each monotherapy in vivo. Collectively, our studies demonstrate that GLP1R agonism and mIDH inhibition induce distinct alterations in mitochondrial redox metabolism that converge to produce synergistic cytotoxicity and provide a mechanistic basis for clinical evaluation of this therapeutic strategy in patients with mIDH glioma.
    DOI:  https://doi.org/10.64898/2026.10.18.759957
  4. Leukemia. 2026 Nov 11.
      Acute myeloid leukemia (AML) is a heterogeneous and aggressive hematologic malignancy associated with poor survival despite recent therapeutic advances. To identify novel anti-leukemic agents, we performed a high-throughput viability screen of 10,000 small molecules across 56 genetically diverse primary AML samples. Compounds with similar activity profiles were grouped into Compound Correlation Clusters (CCCs), leading to the identification of CCC163, which includes AML874, as a potent and selective hit. Integrated pharmacological and CRISPR-Cas9 approaches identified the Mediator complex as the molecular target of AML874. We demonstrated that AML874 acts as a selective CDK8/CDK19 inhibitor, disrupting Mediator-dependent transcription. FLT3-mutated AML showed increased sensitivity to AML874, suggesting a subtype-specific vulnerability. Notably, CDK8 inhibition synergized with venetoclax in AML cell lines and patient-derived xenograft models, resulting in enhanced anti-leukemic activity in vivo. Collectively, these findings establish CDK8/CDK19 inhibition as a therapeutically relevant strategy in AML.
    DOI:  https://doi.org/10.1038/s41375-026-03173-0
  5. Nature. 2026 Nov 11.
      Tumour cells evade detection and elimination by the immune system through a suite of adaptations1, including the repression of antigen presentation, which is required for the recognition of tumour cells by CD8+ T cells. Mitochondria have emerged as targets for enhancing antitumour immunity; however, the extensive mitochondrial proteome has remained largely unstudied for its ability to modulate immune responses. Here we show that defects in the mitochondrial protein import machinery promote tumour immunogenicity and synergize with immune checkpoint blockade treatment in melanoma models. Mitochondrial protein import perturbation, specifically through depletion of the TIM23 import complex subunit TIMM50, enhances tumour immunogenicity through a pathway involving mitochondrial DNA escape, cGAS-STING pathway activation and interferon-β (IFNβ) secretion. Secreted IFNβ signals through the type I IFN receptor to activate the JAK-STAT pathway, resulting in increased antigen presentation on MHC class I complexes. Mitochondrial DNA escape in Timm50-depleted cells is linked to the formation of mitochondrial-derived vesicles. Depletion of SNX9 and RAB9, involved in mitochondrial-derived vesicle formation2, suppresses mitochondrial DNA-dependent type I IFN production and signalling. By disrupting mitochondrial proteostasis and membrane architecture, defective protein import in Timm50-depleted cells drives the immune phenotype. This study shows that mitochondrial protein import inhibition causes tumour immunogenicity, including sensitization to immune checkpoint blockade, by promoting mitochondrial DNA escape and IFNβ-driven MHC class I antigen presentation.
    DOI:  https://doi.org/10.1038/s41586-026-11249-1
  6. Cancer Immunol Res. 2026 Nov 12.
      Natural killer (NK) cells offer a promising off-the-shelf platform for cancer immunotherapy, yet their clinical efficacy is often limited by tumor-intrinsic resistance. Here, we show that loss of core microRNA (miRNA) machinery components, Argonaute‑2 (AGO2) or Ankyrin Repeat Domain 52 (ANKRD52), renders tumor cells hypersensitive to NK cell-mediated killing in both co-culture and xenograft models. Mechanistically, genetic ablation of Ago2 or Ankrd52 impairs miRNA-mediated silencing of critical mitochondrial apoptotic regulators and NK-cell-associated ligands in tumor cells, exemplified by the disrupted repression of pro-apoptotic Bim transcripts by miR-24 and miR-29b, thereby unleashing rapid TNF-α-driven apoptosis. Additionally, metabolic and ultrastructural analyses demonstrate collapsed membrane potential, diminished ATP levels, and fragmented mitochondria in Ago2- or Ankrd52-mutant tumor cells, accompanied by a lower apoptotic threshold upon TNF-α or NK cell challenge. Genome‑wide CRISPR library screen further revealed a selective fitness dependency on mitochondrial electron‑transport and ATP‑synthase genes in mutant tumor cells. Collectively, these findings define defective miRNA machinery as a tumor‑intrinsic vulnerability that couples mitochondrial fragility with increased NK-mediated cytotoxicity, nominate miRNA‑pathway status as a predictive biomarker, and propose that co‑targeting mitochondrial metabolism or apoptosis may potentiate NK‑cell therapies.
    DOI:  https://doi.org/10.1158/2326-6066.CIR-26-0559
  7. Cancer Cell Int. 2026 Nov 13. pii: 361. [Epub ahead of print]26(1):
       BACKGROUND: The Warburg effect, characterized by enhanced glycolysis and lactate production, is a universal feature of cancer cells, even under normoxic conditions. The resulting extracellular acidification and intracellular alkalization create a selective vulnerability that is absent in normal tissues. We previously developed the Warburg Trap (WT) approach, which exploits this vulnerability by combining inhibitors of mitochondrial complex I with H+-ionophores to collapse pH homeostasis and energy balance, thereby inducing cancer-specific cell death. Given that the bone marrow microenvironment in multiple myeloma (MM) is markedly acidic (pH 6.7-6.8 compared to ~ 7.4 in normal bone marrow), we hypothesized that MM cells would be highly sensitive to WT treatment.
    METHODS: The effects of individual WT drugs and drug combinations on three human myeloma cell lines (hMCLs), primary MM cells and one non-neoplastic human osteoblast-like cell line (hOBs) were analyzed in vitro. To evaluate the cytotoxic effects, the IC50 values of the drugs were calculated, and the Zero Interaction Potency (ZIP) model was used to identify possible synergies. Cell viability, intracellular pH values (pHi), the invasive potential, apoptosis induction, glucose uptake, ATP levels, mitochondrial depolarization and glucose transporter expression were analyzed using fluorescence microscopy, flow cytometry, RT-qPCR analysis and various in vitro assays.
    RESULTS: Combinations of the mitochondrial complex I inhibitors metformin (Me) and fenofibrate (Fe) with one of the H+-ionophores drotaverine (Dro) or monensin (Mo) significantly induced apoptosis in hMCLs and primary MM cells, while hOBs remained unaffected. The triple medication regimen exhibited a clear synergistic effect compared to monotherapy. Mechanistic analyses revealed a pronounced drop in pHi, disruption of glucose metabolism, depletion of ATP and loss of mitochondrial potential in response to these drugs. Furthermore, the WT drugs suppressed the invasive potential of MM cells and induced the upregulation of the stress-associated gene DDIT3 and the encoded CHOP protein. RT-qPCR profiling of solute carrier family 2 A (SLC2A) genes, encoding glucose transporters (GLUTs) revealed that SLC2A1, SLC2A8 and SLC2A9 were the most abundant transcripts in MM cells, with SLC2A8 showing the most pronounced difference between MM cells and non-neoplastic hOBs. Additionally, SLC2A8 expression associated with the observed WT-drug sensitivity of the analyzed cell lines.
    Keywords:  Cancer metabolism; Metabolic cancer therapy, Metformin; Multiple myeloma; Warburg Trap; Warburg effect
    DOI:  https://doi.org/10.1186/s12935-026-04504-y
  8. Res Sq. 2026 Oct 20. pii: rs.3.rs-11310455. [Epub ahead of print]
      Damaged mitochondria are cleared by PINK1-Parkin mitophagy, but the pathway is incompletely understood in vivo. Here, we developed MitoFLUX-EM, combining electron microscopy with nanoscale ¹⁵N isotope tracing to resolve the temporal sequence of mitophagy intermediates in vivo, and applied it to a cardiomyopathy mouse model (CHCHD10 S59L) with high PINK1-dependent mitophagy. Unexpectedly, we found that damaged mitochondria are directly captured by pre-existing mitolysosomes, resulting in multisegmented mitolysosomes that sequestered as many as 33 mitochondria at distinct stages of ultrastructural degradation. Autophagosomal-like membranes arising from the mitolysosomes preferentially engaged the intact outer membrane of damaged mitochondria and neither protein removal nor rupture of the outer membrane was required for mitophagy, contrary to prior models. Pink1 loss disrupted this pathway, causing accumulation of aggregates within mitochondria and reduced survival. These findings reveal that PINK1-dependent mitophagy proceeds through a novel form of microautophagy to safeguard cardiac mitochondrial quality in vivo and establish MitoFLUX-EM as a platform for resolving organelle turnover.
    DOI:  https://doi.org/10.21203/rs.3.rs-11310455/v1
  9. Elife. 2026 Nov 11. pii: RP109761. [Epub ahead of print]15
      Mitochondrial dysfunction and declining ATP production are common features of aging, yet whether ATP availability itself directly regulates cellular lifespan is unclear. However, the causal relationship between cellular ATP homeostasis and aging has not been established. Here, we developed a synthetic system to manipulate intracellular ATP independently of endogenous energy production by expressing a plasma membrane-targeted nucleotide transporter, NTT1, from the intracellular parasite Encephalitozoon cuniculi in Saccharomyces cerevisiae. NTT1 expression depleted intracellular ATP in the absence of extracellular ATP, whereas ATP supplementation produced robust NTT1-dependent ATP uptake, and increased intracellular ATP abundance. ATP availability strongly influenced replicative lifespan: ATP depletion shortened lifespan, whereas ATP supplementation restored and extended lifespan in NTT1-expressing cells. Unexpectedly, extracellular ATP also extended lifespan in wild-type cells that lack ATP import, revealing an NTT1-independent response to extracellular ATP. Transcriptomic analyses showed that NTT1-mediated ATP import suppresses glucose uptake, carbohydrate catabolism, mitochondrial respiration, and autophagy, whereas extracellular ATP elicits a distinct transcriptional response in wild-type cells involving metabolic, mitochondrial, and signaling pathways. Single-cell aging analyses further showed that ATP supplementation extends lifespan across distinct aging trajectories and shifts cells away from the mitochondrial dysfunction-associated aging state. Finally, experiments in cells lacking mitochondrial DNA separated these effects mechanistically: NTT1-associated lifespan phenotypes and high-ATP toxicity required functional mitochondria, whereas extracellular ATP extended lifespan in wild-type cells independently of mitochondrial respiration. Together, these findings demonstrate that ATP availability is a direct regulator of cellular aging and reveal distinct metabolic and extracellular ATP-responsive routes through which cellular energy state influences longevity.
    Keywords:  ATP; S. cerevisiae; aging; cell biology; energy metabolism; mitochondria; nucleotide transport; yeast
    DOI:  https://doi.org/10.7554/eLife.109761